Posted by Michael Wonder on 26 Jul 2024
Mirum’s Livmarli now approved for PFIC in patients 12 months and older
25 July 2024 - Mirum Pharmaceuticals today announced that the US FDA has approved a label expansion for Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis.
The expanded label includes use in progressive familial intrahepatic cholestasis patients 12 months and older as well as the higher concentration formulation of Livmarli evaluated in the MARCH Phase 3 study.
